OverviewSuggest Edit

Innovus Pharmaceuticals is an emerging over-the-counter (OTC) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharmaceuticals delivers innovative and uniquely presented and packaged health solutions through its OTC medicines and consumer and health products, which the Company markets directly, commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through its on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (ANDA) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
TypePublic
Founded2011
HQSan Diego, US
Websiteinnovuspharma.com

Latest Updates

Employees (est.) (Sept 2019)18(-14%)
Revenue (FY, 2018)$24 M(+173%)
Share Price (Mar 2020)$1.2

Key People/Management at Innovus Pharmaceuticals

Randy Berholtz

Randy Berholtz

Executive Vice President, Corporate Development and General Counsel
Bassam Damaj

Bassam Damaj

Chairman of the Board, President and Chief Executive Officer
Ryan Selhorn

Ryan Selhorn

Vice President, Chief Financial Officer
Show more

Innovus Pharmaceuticals Office Locations

Innovus Pharmaceuticals has offices in San Diego and Englewood
San Diego, US (HQ)
8845 Rehco Rd
Englewood, US
373 Inverness Pkwy #206
Show all (2)

Innovus Pharmaceuticals Financials and Metrics

Innovus Pharmaceuticals Revenue

Innovus Pharmaceuticals's revenue was reported to be $23.99 m in FY, 2018
USD

Revenue (Q3, 2019)

5.8m

Gross profit (Q3, 2019)

3.5m

Gross profit margin (Q3, 2019), %

61.5%

Net income (Q3, 2019)

(2.2m)

EBIT (Q3, 2019)

(1.7m)

Market capitalization (17-Mar-2020)

3.4m

Closing stock price (17-Mar-2020)

1.2

Cash (30-Sept-2019)

955.0k

EV

9.1m
Innovus Pharmaceuticals's current market capitalization is $3.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

6.6k655.1k730.7k4.8m8.8m24.0m

Cost of goods sold

1.8k292.1k340.7k1.1m1.8m4.3m

Gross profit

4.8k363.0k390.0k3.7m7.0m19.7m

Gross profit Margin, %

73%55%53%78%79%82%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

396.0166.0166.1k113.8k118.1k196.9k183.5k179.7k225.5k1.0m1.9m2.2m2.0m2.2m4.5m7.3m7.4m5.4m6.8m5.8m

Cost of goods sold

117.055.9k50.5k51.3k76.4k64.0k102.4k1.5m1.8m2.4m2.2m

Gross profit

279.0110.2k63.2k66.8k120.4k119.4k77.4k5.8m3.6m4.5m3.5m

Gross profit Margin, %

70%66%56%57%61%65%43%79%67%66%62%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

25.0k18.4k33.4k7.5k55.9k829.9k1.6m1.2m

Accounts Receivable

216.6k191.6k83.1k33.6k68.3k282.0k

Prepaid Expenses

35.3k55.0k53.3k863.7k363.1k1.1m

Inventories

177.9k266.0k254.4k599.9k1.7m2.4m
USDY, 2019

EV/EBIT

-5.4 x

EV/CFO

-4.9 x

Revenue/Employee

295.1k

Financial Leverage

-4.8 x
Show all financial metrics

Innovus Pharmaceuticals Online and Social Media Presence

Embed Graph

Innovus Pharmaceuticals News and Updates

Innovus Pharmaceuticals Continues Strong Revenue Growth & New Product Rollouts

CEOLIVE Exclusive Interview with Dr. Bassam Damaj, President & CEO of Innovus Pharmaceuticals (INNV)Orlando, FL - (NewMediaWire) - April 2, 2019 - CEOLIVE, a provider of in-depth video interviews with public company CEO’s, announced the release of the latest episode of CEORoadshow featuring…

Global Sexual Enhancement Supplements Market outlook to 2023 | Industry Top Key Players – Innovus Pharmaceuticals, Doc Johnson, Reckitt Benckiser, Leading Edge Health, Lovehoney, Pound International

Wiseguyreports.Com Adds “Sexual Enhancement Supplements - Market Demand, Growth, Opportunities, Manufacturers and Analysis of Top Key Players to 2023” To Its Research Database Posted via Industry Today. Follow us on Twitter @IndustryToday

Sexual Enhancement Supplements Material Market 2018 Global Analysis By Key Players – Leading Edge Health, Innovus Pharmaceuticals, Direct Digital, SizeGenix, Vimax

Wiseguyreports.Com adds “Sexual Enhancement Supplements Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday

Innovus Pharmaceuticals Frequently Asked Questions

  • When was Innovus Pharmaceuticals founded?

    Innovus Pharmaceuticals was founded in 2011.

  • Who are Innovus Pharmaceuticals key executives?

    Innovus Pharmaceuticals's key executives are Randy Berholtz, Bassam Damaj and Ryan Selhorn.

  • How many employees does Innovus Pharmaceuticals have?

    Innovus Pharmaceuticals has 18 employees.

  • What is Innovus Pharmaceuticals revenue?

    Latest Innovus Pharmaceuticals annual revenue is $24 m.

  • What is Innovus Pharmaceuticals revenue per employee?

    Latest Innovus Pharmaceuticals revenue per employee is $1.3 m.

  • Who are Innovus Pharmaceuticals competitors?

    Competitors of Innovus Pharmaceuticals include Biogen, AbbVie and Athersys.

  • Where is Innovus Pharmaceuticals headquarters?

    Innovus Pharmaceuticals headquarters is located at 8845 Rehco Rd, San Diego.

  • Where are Innovus Pharmaceuticals offices?

    Innovus Pharmaceuticals has offices in San Diego and Englewood.

  • How many offices does Innovus Pharmaceuticals have?

    Innovus Pharmaceuticals has 2 offices.